RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

EJ Helden, L (Lindsay) Angus, CW Menke-van der Houven van Oordt, DAM Heideman, E Boon, SC van Es, SA Radema, CML van Herpen, DJA de Groot, E G de Vries, Maurice Jansen, Stefan Sleijfer, HMW Verheul

Research output: Contribution to journalArticleAcademic

20 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2361-2374
Number of pages14
JournalMolecular Oncology
Issue number11
Publication statusPublished - 2019

Cite this